Rosario Notaro
Overview
Explore the profile of Rosario Notaro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Roth A, Piatek C, et al.
Ann Hematol
. 2025 Jan;
104(1):81-94.
PMID: 39841198
Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) following positive results from two pivotal trials in patients with PNH...
2.
Risitano A, Frieri C, Marano L, Urciuoli E, Sanseverino A, Nannelli C, et al.
Am J Hematol
. 2024 Oct;
100(1):163-167.
PMID: 39394926
No abstract available.
3.
Di Matteo S, Freilone R, Bruno G, Notaro R, Moumene S, Martone N, et al.
Clinicoecon Outcomes Res
. 2024 Apr;
16:225-232.
PMID: 38623087
Background: Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease characterized by hemolytic episodes and associated with significant clinical burden. The introduction of C5 inhibitory monoclonal antibodies (C5i) represented a major...
4.
Peffault de Latour R, Roth A, Kulasekararaj A, Han B, Scheinberg P, Maciejewski J, et al.
N Engl J Med
. 2024 Mar;
390(11):994-1008.
PMID: 38477987
Background: Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors. Iptacopan,...
5.
Sica M, Notaro R
Am J Hematol
. 2024 Jan;
99(3):505-507.
PMID: 38264841
C3 binding on PNH red blood cells after in vitro complement activation in normal and terminal complement depleted (∆5, ∆6, ∆9) sera: C3 binding, and the subsequent extravascular hemolysis, happens...
6.
Luzzatto L, Nannelli C, Notaro R
Am J Hum Genet
. 2023 Nov;
110(11):1983-1985.
PMID: 37922885
No abstract available.
7.
Conte B, Boni L, Bisagni G, Durando A, Sanna G, Gori S, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5217-5226.
PMID: 37888299
Purpose: In estrogen receptor-positive (ER+) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect aromatase inhibitors (AI) metabolism and efficacy. Here, we assessed the impact of SNP on...
8.
Cosi I, Moccia A, Pescucci C, Munagala U, Di Giorgio S, Sineo I, et al.
Sci Rep
. 2023 Mar;
13(1):5267.
PMID: 37002241
ETV4, one of ETS proteins overexpressed in prostate cancer, promotes migration, invasion, and proliferation in prostate cells. This study identifies a series of previously unknown ETV4 alternatively spliced transcripts in...
9.
Sica M, Barone F, Nannelli C, Ricci P, Marano L, De Angioletti M, et al.
Br J Haematol
. 2023 Jan;
201(1):e1-e4.
PMID: 36660816
No abstract available.
10.
Girmenia C, Barcellini W, Bianchi P, Di Bona E, Iori A, Notaro R, et al.
Blood Rev
. 2022 Sep;
58:101013.
PMID: 36117056
This article presents the results of group discussion among an ad hoc constituted panel of experts aimed at identifying and addressing unmet clinical needs (UCNs) in the management of infectious...